Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mirfulan
- Development stage
- Unknown
- Lead developer
- Recordati
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Mirfulan is a multi-ingredient topical wound and healing ointment primarily composed of zinc oxide and cod liver oil. Developed by Merckle Recordati GmbH, it is indicated for the treatment of non-infected acute and subacute skin damage, including diaper dermatitis, skin wounds, and conditions accompanied by redness, itching, and pain. The formulation leverages the astringent and protective properties of zinc oxide alongside the regenerative support of cod liver oil (rich in Vitamins A and D3) and urea. It is marketed in Germany as a pharmacy-only product and has been evaluated in clinical settings for its efficacy in improving transepidermal water loss (TEWL) and accelerating the healing of suction blister wounds.
- Brand names
- MirfulanMirfulan Spray N
- Other names
- Mirfulan ointment
02
Targets
RXRB (Retinoid X receptor beta)RARB (Retinoic acid receptor beta)KRT (Keratin and other superficial epidermal proteins)RXRA (Retinoid X receptor alpha)RARG (Retinoic acid receptor gamma)RARA (Retinoic acid receptor alpha)VDR (Vitamin D receptor)RXRG (RXRγ)
Beyond the preview
Go deeper on Mirfulan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirfulan.